Letters sent to healthcare professionals in January 2016

In January 2016, letters were sent to healthcare professionals regarding fingolimod (Gilenya▼) and erlotinib (Tarceva)

In January 2016, letters were sent to healthcare professionals to notify about safety information for:

  • Fingolimod (Gilenya▼): risks related to effects on the immune system
  • Erlotinib (Tarceva): first-line maintenance indication now restricted to patients with a tumour that has an EGFR-activating mutation

Article citation: Drug Safety Update volume 9 issue 6 February 2016: 3.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.